Signature Diagnostics Receives Extended Patent Protection for its Proteasome-Complex Inhibitors
(Thomson Reuters ONE) -
Signature Diagnostics /
Signature Diagnostics Receives Extended Patent Protection for its
Proteasome-Complex Inhibitors
Processed and transmitted by Thomson Reuters.
The issuer is solely responsible for the content of this announcement.
* Company currently seeking development partners for these drug candidates
Potsdam, Germany, December 07, 2010 - Signature Diagnostics AG announced today
that the European Patent Office (EPO) has granted a new patent providing
extended protection for drug molecules licensed by the company from the
Technical University of Darmstadt. The new patent (EP 1858913) covers peptide-
mimetics and their use as inhibitors of the human proteasome complex. The
molecules have immediate application in a variety of indications, including
cancer and inflammatory disease. The company is currently seeking cooperation
partners for further development of these proteasome-inhibitor drug candidates.
"This patent further strengthens our strong intellectual property portfolio in
key therapeutic areas such as cancer and inflammation," commented André
Rosenthal, Chief Executive Officer of Signature Diagnostics. "We are committed
to maximizing the patent protection for these drug candidates, as they are
essential value-drivers for the company and its future partners."
About Signature Diagnostics AG
Signature Diagnostics AG is a molecular diagnostics company based in Potsdam,
Germany, focusing on the development and commercialization of novel molecular
oncology diagnostic products for early detection (screening) and prognosis of
cancer. The company has completed development of its first two diagnostic
products for colorectal cancer screening ("Detector C/C+") and prognosis
("Predictor C"), which will be launched in 2011 in its own ISO 15189 certified
service laboratory. Using its state-of-the-art technologies in tissue and blood
sample collection, molecular pathology, Xenopatient(TM) platform, genome-wide
profiling, data mining, and biostatistics, the company collaborates with
clinical, pharmaceutical, and diagnostic partners. Signature Diagnostics
sponsors and conducts large prospective, multicenter clinical trials with more
than 30 primary care hospitals and several dozen colonoscopy centers in Germany
to discover and validate biomarkers in oncology.
For questions, please contact:
Dr. Rainer Kramer, CBO
Signature Diagnostics
Hermannswerder 20A
14473 Potsdam, Germany
Tel: +49-331-2000-208
PR(at)signature-diagnostics.de
--- End of Message ---
Signature Diagnostics
Hermannswerder 20 A Potsdam Germany
Press release (PDF):
http://hugin.info/143237/R/1469628/406932.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Signature Diagnostics via Thomson Reuters ONE
[HUG#1469628]
Unternehmensinformation / Kurzprofil:
Datum: 07.12.2010 - 13:34 Uhr
Sprache: Deutsch
News-ID 49480
Anzahl Zeichen: 3560
contact information:
Town:
Potsdam
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 354 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Signature Diagnostics Receives Extended Patent Protection for its Proteasome-Complex Inhibitors"
steht unter der journalistisch-redaktionellen Verantwortung von
Signature Diagnostics (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
